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ABBREVIATION 
 
 
 
 
 
 5’UTR: 5 prime untranslated region 
 BFU-MK: burst-forming unit-megakaryocyte 
 BM: bone marrow 
 C: cysteine 
 CDKI: cyclin-dependent kinase inhibitor 
 CFU-MK: colony-forming unit-megakaryocyte 
 CLP: common lymphoid precursor 
 CMP: common myeloid precursor 
 CRM: cytokine receptor homology module 
 CXCR4: CXC chemokine receptor 4 
 DMS: demarcation membrane system 
 DNA: deoxyribonucleic acid 
 ECM: extracellular matrix 
 EPO: erythropoietin 
 ET: essential thrombocythemia 
 ETP: earliest thymic progenitors 
 FGF4: fibroblast growth factor 4 
 FOG: friend of GATA 
 G: glycine 
 GMP: granulocyte−macrophage progenitor 
 GSN: gelsolin 
 HGF: hematopoietic growth factor 
 HSC: hematopoietic stem cell 
 HT: hereditary thrombocytosis 
 IBD: increased identical by descendent 
 IFNγ: interferon gamma 
 IL: interleukin 
 JAK: janus kinase 
 K: lysine 
 M: methionine 
 MAP: mitogen activated protein 
 MEP: MK/Erythro progenitor 
 MK: megakaryocyte 
 MPD: myeloproliferative disorder 
 MPN: myeloproliferative neoplasm 
 MPP: multipotent progenitor 
 N: asparagine 
 NF-E2: nuclear factor erythroid 2 
 NGS: next generation sequencing 
 NO: nitric oxide 
 PCR: polymerase chain reaction 
 PFCP: primary familial and congenital polycythemia 
 PI3K: phosphatidylinositol 3 kinase 
 RFLP: restriction fragment length polymorphism 
 RGS16: regulator of G protein signaling 
 SCF: stem cell factor 
 SDF1: stromal cell-derive factor 1 
 SIFT: sorting tolerant from tolerant 
 SNP: single nucleotide polymorphism 
 SOCS: suppressor of cytokine signaling 
 STAT: signal transducer and activator of transcription 
 STR: short tandem repeat 
 TF: transcription factor  
 THPO: thrombopoietin gene 
 TNFα: Tumor Necrosis Factor alpha 
 TPO: thrombopoietin 
 uATG: upstream initial codon 
 uORF: upstream open reading frame 
 V: valine 
 Y: tyrosine 
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1. SUMMARY 
 
 
 
 
Hereditary thrombocythemia (HT) is a familial myeloproliferative disorder 
characterized by an elevated platelet count in peripheral blood. Thrombocytosis is 
due to a genetic alteration that can be transmitted to the offspring. Recently, major 
progress has been made in understanding the biology of HT thanks to the discovery 
of mutations in two genes: thrombopoietin (THPO) and its receptor MPL. 
Interestingly, the analysis of these mutations has provided more insights in the 
physiological regulation of platelet homeostasis 1. However, not all the HT pedigrees 
carry mutations in the THPO or MPL genes. In 80-90% of these pedigrees the 
disease-causing gene remains unknown 2 and it is likely that hereditary 
thrombocytosis can be caused by alterations in other genes, not yet identified.  
 
The focus of my PhD studies was a large US family affected by HT. In this family, 
THPO and MPL were excluded as disease-causing genes. Therefore, genome-wide 
linkage analysis was performed to identify co-segregating regions shared by the 
affected family members as a target in search of possible candidate mutations 
responsible for the thrombocytosis phenotype. One region with significant logarithm 
of odds (LOD) score values has been located using microsatellites and SNP chip 
arrays. One novel candidate mutation was found in the gelsolin gene by next 
generation sequencing and confirmed by capillary sequencing in all the 12 affected 
family members. Gelsolin is a Ca2+ regulated actin filament severing, capping and 
nucleating protein abundant in platelets. It is involved in the regulation of cell 
structure and metabolism. Interestingly, it has a key-role in apoptosis regulation and 
modulation of platelets.  Computational predictions showed that this alteration can 
probably affect protein function and the structural analysis indicated that the 
alteration is located at the interface with actin.  The platelets-biogenesis in vitro assay 
showed that the candidate alteration can increase the release of platelets-like 
particles in DAMI cell line stably transfected with the mutant gelsolin. To study the in 
vivo role of the candidate mutation in the pathogenesis of HT, different mouse 
models have been established. In lethally irradiated recipient mice transplanted with 
BM cells transduced with retrovirus expressing the human mutant gelsolin, variations 
Summary 
 2 
in platelet counts in peripheral blood have been observed. Transgenic mice 
expressing the human mutant gelsolin were generated to fully characterize the new 
discovered alteration. These mice developed a tendency to elevated platelet counts 
compared to their wild type littermates.  
 
Taken together, these data illustrate the discovery of a new candidate mutation 
associated with the pathogenesis of HT. Until now, mutations in gelsolin gene were 
never described except for a mutant (D187N/Y) plasma gelsolin responsible for 
familial amyloidosis of Finnish type (FAF). My work contributed to further characterize 
this gene and to link it with the pathogenesis of HT.  
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2. INTRODUCTION 
 
 
 
 
2.1 HEMATOPOIESIS 
 
Hematopoiesis is the lifelong process by which all the blood cells are produced. This 
dynamic process is highly regulated in order to fulfil the requirements of the body for 
the transport of oxygen, blood coagulation and immune response. 
In humans, hematopoiesis starts in the yolk sac during the first few weeks of 
gestation and then moves to fetal liver and spleen until 6 to 7 months, when the bone 
marrow (BM) becomes the main site of blood production and remains the major 
source of new blood cells throughout normal life 3.  
Hematopoiesis is a hierarchical system. At the top, hematopoietic stem cells (HSCs) 
reside in specialized microenviroments, known as bone marrow niche. In humans, 
HSCs are defined by the expression of the CD34, CD133, Thy-1 and c-Kit antigens 
and the absence of lineage markers and CD38 4. HSCs are maintained in a 
quiescent state in order to minimize stresses due to cellular respiration and genome 
replication helping to HSC longevity and function 5. In this way, HSCs can persist for 
a lifetime and give rise to progenitor cells that become increasingly lineage restricted 
and ultimately differentiate into all lineages of mature blood cells. Thanks to its self-
renewal capability, the pool of HSC remains constant in a normal healthy steady 
state. HSCs reside at the apex of hematopoietic hierarchy and they are connected to 
mature cells by a complex roadmap of progenitor intermediates. HSCs differentiate 
into multipotent progenitors (MPPs) that further segregate along two fundamental 
branches: myeloid and lymphoid. The earliest myelo-lymphoid split gives rise to 
common myeloid precursors (CMP) and immature lymphoid precursors (MLP) and 
each of these undergo further commitment steps. CMPs give rise to GMPs, which 
become committed to the granulocyte-monocyte fate, and MEPs, which only produce 
erythroid and megakaryocyte cells. On the lymphoid side, MLPs give rise to B and 
NK cell precursors and the earliest thymic progenitors (ETPs) committed to the T 
lineage (Fig.1). The molecular mechanisms that regulate the balance between the 
self-renewal and differentiation are typically associated with changes in gene 
expression and are driven by transcription factors 6.   
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Fig.1: The hierarchy of hematopoietic cells in human. HSCs are defined by the expression of the 
CD34 and the absence of lineage markers and CD38. MPP, multipotent progenitor; CMP, common 
myeloid progenitor; MEP, megakaryocyte/erythroid progenitor; GMP, granulocyte−macrophage 
progenitor; MLP, immature lymphoid progenitors; ETP, earliest thymic progenitors. Adapted from 
6
 
 
Hematopoiesis is tightly regulated through interactions between progenitor cells and 
various growth factors. Hematopoietic growth factors are key external regulators of 
HSCs. They sustain survival, proliferation, differentiation and maturation of 
hematopoietic cells at all stages. These growth factors are glycoprotein hormones 
that can act locally at the site where they are produced or circulate in plasma. They 
also bind to the extracellular matrix to form niches to which stem and progenitor cells 
can adhere. The biological activity of growth factors is mediated by specific receptors 
on the cell surface. Most of these receptors are from the haematopoietin receptor 
superfamily. Upon the binding with their ligand, the receptors dimerize and give rise 
to a series of intracellular signal transduction pathway. The major ones are: 
JAK/STAT, the mitogen activated protein (MAP) kinase and the phosphatidylinositol 
3 kinase (PI3K) pathways 3. 
 
2.2 MEGAKARYOCYTOPOIESIS 
 
Megakaryocytopoiesis is the process that leads to the production of platelets. It 
involves the commitment of hematopoietic stem cells and the proliferation, maturation 
and terminal differentiation of megakaryocytic progenitors. This process is 
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characterized by DNA endoreduplication, cytoplasmic maturation and expansion, and 
release of cytoplasmic fragments as circulating platelets. An overview of 
megakaryocyte (MK) production of platelets is shown in figure 2 (Fig.2).  
 
 
Fig.2:  Overview of platelets biogenesis. As megakaryocytes transition from immature cells (A) to 
released platelets (E), a systematic series of events occurs. (B) The cells first undergo nuclear 
endomitosis, organelle synthesis, and cytoplasmic maturation and expansion, while a microtubule 
array, emanating from centrosomes, is established. (C) Prior to the onset of proplatelet formation, 
centrosomes disassemble and microtubules translocate to the cell cortex. Proplatelet formation 
initiates with the development of thick pseudopods. (D) Sliding of overlapping microtubules drives 
proplatelet elongation as organelles are tracked into proplatelet ends, where nascent platelets 
assemble. Proplatelet formation continues to expand throughout the cell while bending and branching 
amplify existing proplatelet ends. (E) The entire megakaryocyte cytoplasm is converted into a mass 
of proplatelets, which are released from the cell. The nucleus is eventually extruded from the mass of 
proplatelets, and individual platelets are released from proplatelet ends. 
7
 
 
Each day in every human, approximately 1 x 1011 platelets are produced. It has been 
estimated that a mature MK release around 2000-3000 platelets 8. Platelets are 
anucleated cells that play an essential role in thrombosis and hemostasis. Blood 
platelets appear as small oval discs with average size of 2.5 x 5.0 m. Platelets 
contain multiple cellular organelles including mitochondria, lysosomes, granules and 
peroxisomes.  
 
Introduction 
 6 
     2.2.1 From MK/Erythro progenitor (MEP) to MK 
 
The MK and erythroid lineages are closely linked and have a common bipotent 
progenitor called MEP. In humans, the MEP is defined as Lin- CD34+ CD38+ IL3Ra- 
D45RA-2. This bipotent progenitor commits to the MK lineage through MK progenitors 
capable of proliferating and to give rise in vitro to MK colonies. BFU-MK are the most 
primitive MK-committed progenitors with the highest aptitude to proliferate. CFU-MK 
have a lower proliferation capacity. In humans, MK progenitors have been 
characterized by the presence of the surface markers CD34, CD31 and the CD133. 
CD41a ( integrin chain gpIIb/IIIa complex) and CD41b (β integrin chain of 
glycoprotein IIb) are specific for the MK lineage. Only about 3% of the CD34+ marrow 
cells express CD41. This fraction of cells includes MK progenitors, but does not 
contain all the CFU-MK (Fig.3). CD41 expression precedes CD42, the expression of 
which corresponds to a later differentiation step and correlates with the presence of 
other molecules such as Mpl, GPVI (collagen receptor), 12 integrin, CD36 and 
proteins contained in the -granules (PF4, vWF) 9.  
 
 
Fig.3: expression of differentiation markers along the human megakaryocytic differentiation. BFU-
MK, burst-forming unit-megakaryocyte; CFU-MK, colony-forming unit-megakaryocyte; PMKB, pro-
megakaryoblast; proMK, pro-megakaryocyte; MK, megakaryocyte. Adapted from 
9
. 
 
     2.2.2 Megakaryocytes development and platelets formation 
 
After the initiation of the synthesis of platelet proteins, the MK precursor (also called 
promegakaryoblast) begins to enlarge and to increase its ploidy through a process of 
endomitosis. The MK is one of the rare cells that are polyploid during normal 
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differentiation. MKs can stop DNA duplication at any stage between 2N and 64N, and 
possibly 128N. In humans, the modal ploidy is 16N (about 50% of MKs). 
Interestingly, the MK ploidy increases during ontogeny with low ploidy MKs in 
primitive hematopoiesis (embryos) compared to adult MKs 10. An endomitosis, 
similarly to mitosis, begins with a duplication of the centrosomes; a normal prophase 
with development of a mitotic spindle, chromatin condensation and the rupture of the 
nuclear envelope; alignment of the chromosomes on the equatorial plate occurs 
during the metaphase and finally the sister chromatids separate at anaphase. The 
spindle of a poliploid MK is multipolar with the number of poles corresponding to the 
ploidy level. The endomitosis fails of late cytokynesis leading to the formation of a 
MK containing a single nucleus with a single nuclear membrane. In MKs the cell 
cycle is composed of a succession of G1, S, G2 and M phases, but the M phase is 
incomplete. After M phase, MKs re-enter into G1 to initiate a subsequent cell cycle 9. 
In addition to expansion of DNA, megakaryocytes experience significant maturation 
as internal membrane system, granules and organelles. The invagination of the MK 
plasma membrane creates a demarcation membrane system (DMS) that constitutes 
a membrane reservoir for platelets formation. The DMS associates with both the 
microtubules and the actin filaments and it is evaginated to form pseudopodal 
processes during proplatelet formation. Platelets are formed by fragmentation of the 
proplatelet protrusion and this process occurs in the blood circulation. Together with 
the DMS, microtubules and acto-myosin complex are the main determinants of 
platelets shedding 11. Microtubules constitute the protrusion forces that allow 
proplatelet formation. The driving force for proplatelet elongation is not microtubules 
polymerization but microtubule sliding. Proplatelets fail to form in megakaryocytes 
treated with agents that inhibit microtubule assembly 12. Microtubules also play an 
important role in organelle transport in proplatelets 9. The role of acto-myosin is not 
completely understood. Actin polymerization does not play a major role in 
proplatelets extension. However, it is required for proplatelets branching and thus 
may be important for the regulation of platelets production. MKs treated with one of 
the actin toxins (cytochalasin, latrunculin) can extend long proplatelets but fail to 
branch 13 11.  
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     2.2.3 Apoptosis in platelets biogenesis 
 
Apoptosis is a programmed form of cell death. Morphologically, it is defined by cell 
membrane blebbing, cell shrinkage, chromatin condensation and DNA fragmentation. 
In metazoan cells, apoptosis is regulated by two highly conserved pathways: the 
extrinsic one (triggered by ligands such as Fas ligand, TNF) and the intrinsic or 
mitochondrial one. Both share a common end point: the activation of proteolytic 
enzymes called caspases, which mediate the rapid dismantling of cells. In viable 
cells, caspases reside in the cytosol as inactive precursors and they will be activated 
only upon precise stimuli. 
Since the initial observation that platelets release from megakaryocytes resembles 
the onset of apoptosis 14, an increasing body of evidence has suggested that 
platelets shedding is an apoptotic process. Megakaryocytes possess both an intrinsic 
and an extrinsic apoptosis pathway, which they might restrain in order to survive and 
at the same time they may need it to facilitate platelets shedding. Once released in 
circulation platelets fate depends on the Bcl-2 family proteins. In particular, Bcl-XL is 
the key player for platelets survival (Fig.4) 15. 
 
 
Fig.4: Apoptotic pathways and processes in the megakaryocyte lineage. While the critical players 
have yet to be identified, current evidence suggests that megakaryocytes possess both an intrinsic 
and extrinsic apoptosis pathway. Once released into the circulation, platelets depend on the Bcl-2 
family protein Bcl-xL for their survival. Bcl-xL restrains the pro-death protein Bak until the end of the 
platelet's life span, when it is presumed apoptosis is initiated to facilitate clearance from the 
circulation. Whether caspases are required, and whether this apoptotic pathway intersects at all with 
agonist-driven activation pathways, remains to be established. 
16
.  
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Overexpression of pro-survival Bcl-XL in megakaryocytes inhibits proplatelets 
formation 17.  Pro-apoptotic factors, including caspase and nitric oxide (NO), are also 
expressed in MKs. Evidence indicating a role for caspases in platelet assembly is 
strong. Caspase activation has been established as a requirement of proplatelet 
formation. Caspase-3 and caspase-9 are active in mature megakaryocytes and 
inhibition of these caspases blocks proplatelet formation 18. As a matter of fact, in 
cultured human megakaryocytes it has been observed cleavage of substrates such 
as gelsolin in cells that had begun to shed platelets 19.  NO, as well as pro-apoptotic 
cytokines such as TNF- and IFN-, can trigger increased release of platelet-like 
bodies from megakaryocytic cell line Meg-01 20. Conversely, a range of 
pathophysiological stimuli, including chemotherapy, is thought to cause 
thrombocytopenia by inducing the apoptotic death of megakaryocytes and their 
progenitors. Recently, Josefsson et al proved that MKs do not activate the intrinsic 
pathway to generate platelets, but they must restrain it to survive and progress safely 
through proplatelet formation and platelets shedding. Their studies demonstrate that 
deletion of pro-apoptotic factors Bak and Bax, the gatekeepers of the intrinsic 
pathway had no adverse effect on MK number, ploidy or proplatelet formation. 
Moreover, genetic deletion of Bak and Bax could block death and rescue proplatelet 
formation in the presence of ABT-737 (proapoptotic agent) and completely restored 
platelets production in mice lacking Bcl-XL. Thus, megakaryocytes require Bcl-XL to 
restrain the activity of Bak and Bax during platelet production. They confirm that MKs 
become dependent on Bcl-XL just as they enter into proplatelet formation and it is not 
required for their growth and development 21.  
Once released into the circulation, platelets encounter one of the two possible fates: 
consumption in a hemostatic process or removal by the reticuloendothelial system in 
liver or spleen. Since only a fraction of the circulating platelets population is required 
to maintain hemostasis at steady state, the majority of platelets die via the second 
way, being cleared after 10 days in humans and 5 days in mice 16 19. First postulated 
by Vanags et al 22, it is now well established that platelets depend on pro-survival 
Bcl-XL to stay alive. The role of Bcl-XL is to restrain pro-death Bak. Deletion of Bak 
nearly doubles circulating platelets life span 15. Thus, the balance between these two 
Bcl-2 family members dictates whether a platelet lives or dies. Differently from MKs, 
only caspase-3 is abundant in platelets, while caspase-9 is absent 7.  These data 
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support differential mechanism for programmed cell death in platelets and 
megakaryocytes. However, it remains unclear how this apoptotic program is 
controlled.  
 
 
     2.2.4 Regulation of megakaryocytopoiesis 
 
MK differentiation is regulated by extracellular and intracellular mechanism. 
Cytokines and numerous components of the bone marrow microenvironment are 
involved in the regulation of MK terminal differentiation. Among cytokines, 
thrombopoietin (TPO), the key player, IL6 and IL11 have a role in MK differentiation. 
In addition, proplatelet formation is tightly regulated by interactions with the stroma 
and the extracellular matrix (ECM). In the marrow, collagen inhibits proplatelet 
formation. When a megakaryocyte starts its migration through the endothelium it 
interacts with some components of the ECM such as fibrinogen, which may induce 
and increase proplatelets formation 23. MK marrow localization and migration are 
regulated by FGF4 and SDF-1. Stromal cell-derived factor 1 (SDF-1) is a CXC 
chemokine whose main receptor is CXCR4, a seven-transmembrane receptor 
coupled to G-protein. SDF-1 is produced locally by stromal cells located in the 
marrow and promotes the migration and contact of immature MK with a permissive, 
endothelial rich BM microenvironment 24.  CXCR4 is expressed along the entire MK 
differentiation pathway from early progenitors to platelets. Albeit the increase in 
CXCR4 expression, mature MK and platelets are poorly reactive to SDF-1. This 
phenomenon is related to a reduced function of the receptor caused by an 
overexpression of RGS16 (regulator of G protein signaling). This induces a decrease 
in retention forces and may explain the MK egress from the marrow 25.   
MK development is controlled by numerous transcription factors (TFs), which form 
complexes that coordinately regulate the chromatin organization to specifically 
activate the genes of MK lineage and concurrently repress gene expression that 
support other cell type. Many MK-specific genes are co-regulated by GATA and 
friend of GATA (FOG) together with acute myeloid leukemia/runt related TF1 
(AML/RUNX1) and ETS proteins. The zinc-finger protein GATA-1 is the principle TF 
directing MK development by functioning both as an activator or repressor depending 
of the protein complex. One of the initial events during MK/E lineage restriction is 
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downregulation on PU.1, the main TF responsible for myeloid cell differentiation and 
upregulation of GATA1. GATA-1 possesses a robust MK-specific genetic program, 
regulating all stages of MK development. In humans, GATA-1 mutations lead to 
severe diseases involving both erythroid cells and MK 26,27. Nuclear factor erythroid 2 
(NF-E2) is a heterodimeric leucine zipper TF that comprises an MK-erythroid specific 
45-kDa subunit (P45) and a non-lineage specific p18 Maf family subunit which 
controls terminal MK maturation, proplatelet formation and platelet release 28 26. Maf 
or P45 mutations in mice result in severe impairment of megakaryocytopoiesis. NF-
E2 deficient mice have profound thrombocytopenia with MK maturation arrest and 
severe platelets deficit 29. 
 
     2.2.4.1 Thrombopoietin  
 
Thrombopoietin (TPO), also known as c-Mpl ligand, is the primary physiological 
growth factor for the MK lineage, which also plays a central role in the survival and 
proliferation of HSC 30. Human thrombopoietin gene (THPO) is located on 
chromosome 3q26.3-3q27. Abnormalities (inversion or deletion) at its chromosomal 
locus are often found in megakaryocytic leukemia and other myeloproliferative 
disorders associated with thrombocytosis 31. The gene contains 5 coding exons and 
2 upstream noncoding exons, which result in a long 5 prime untranslated region 
(5’UTR) with additional 7 upstream initiation codons (uATG). The presence of 7 
uATG inhibits translation by causing premature initiation and thereby preventing the 
ribosome from initiating at the physiological start codon 1. These types of uORF only 
exist in 10% of mRNA transcripts in human and are often found in highly regulated 
genes 32. Different mutations in the 5’UTR regulatory region leading to an 
overexpression of TPO are associated with some cases of familial essential 
thrombocythemia or familial thrombocytosis 33. TPO mRNA produces a 353 amino 
acid precursor protein. The mature molecule is composed of 332 amino acid (95 
kDa) and it is acidic and heavily glycosylated. The TPO protein consists of 2 
domains: the N-terminal and the C-terminal domains. The N-terminal portion 
(residue1-153) has high homology with erythropoietin (EPO) and represents the 
receptor-binding domain of the hormone. The C-terminal part of TPO protein (residue 
154-332) contains a carbohydrate-rich domain that is highly glycosylated and it is 
important in maintaining protein stability 34.  
Introduction 
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TPO is mainly produced in the liver and to a minor degree in the kidney, spleen, and 
other organs. The normal serum concentration of TPO is very low, ranging between 
0.5 and 2 pmol/L 35. Its production is constitutive and it is independent from the actual 
platelet concentration in blood. Plasma TPO concentration is regulated by the 
targets, because megakaryocytes and platelets metabolize the hormone via binding 
to the receptor. Levels of TPO are usually inversely related to BM MK mass and 
platelet counts 33. Thus, megakaryocytopoiesis is regulated by plasma levels of 
unbound TPO, which reflects the balance between constitutive production and rate of 
destruction that is generally dictated by the overall platelets production 36.  
 
     2.2.4.2 TPO receptor: c-Mpl 
 
The TPO receptor, c-Mpl, is a typical type I hematopoietic growth factor (HGF) 
receptor and contains 2 cytokine receptor homology modules (CRMs). Biochemical 
and crystallographic data show that TPO binds only the distal CRM (CRM1) and 
thereby initiates signal transduction. Therefore, CRM1 acts as an inhibitor of c-Mpl 
that is relieved upon the binding with TPO. Whether TPO causes dimerization of the 
receptor or simply stabilize dimers is unclear. The thrombopoietin receptor is 
expressed primarly in hematopoietic tissues, specifically in MKs, their precursors and 
their progeny (platelets). C-Mpl is constitutively expressed on the surface of these 
cells and its display is regulated by the thrombopoietin binding and receptor 
internalization  37. Upon binding ligand, the receptor is activated to transmit numerous 
biochemical signals (Fig.5). The HGF receptors exist in a homodimeric state in the 
absence of the ligand and in this conformation the cytoplasmic domains are 
separated. After the binding with the hormone, there is a conformational change 
bringing the domains in contact with each other. Several studies indicate that the 
cytoplasmic domains of the receptor bind the JAK kinases also in the inactive state. 
But the activation of the kinases, through cross-phosphorylation, occurs only with the 
closer juxtaposition of the enzymes reached after the onset of the signal transduction 
37. 
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Fig.5: Mechanism of activation of the TPO receptor. TPO binds the distal CRM (CRM 1) of the 
inactive TPO (c-Mpl) receptor and inducing a conformational change that initiates many downstream 
signal transduction events. STAT, signal transducer and activator of transcription; JAK, janus kinase; 
MAPK, mitogen activated protein kinase; RAS, GTPase protein; RAF, serine/threonine-specific 
protein kinases; SHC-GRB2, adaptor proteins; SOS, son of sevenless (guanine nucleotide exchange 
factor). 34. 
 
Once JAK kinases are active, they phosphorylate different tyrosine residues (Y) on 
the receptor itself creating docking sites (P-Y) for signaling molecules that contain 
Shc homology (SH)2 or phosphotyrosine-binding (PTB) motifs. Numerous signaling 
molecules mediate the signal transduction events: signal transducer and activators of 
transcription (STATs) and phosphoinositol-3-kinase (PI3K) leading to cell survival 
and proliferation; the mitogen-activated protein kinases (MAPKs) promoting 
differentiation events and activation of anti-apoptotic pathways that promote cellular 
viability. After stimulation, the induced signal must be limited through different 
mechanism. First, the docking sites at the receptor can recruit suppressor molecules 
such as SOCS proteins and some phosphatases like SHP1, SHIP1 and PTEN 38 39. 
SOCS proteins are induced by STAT-mediated transcription and once translated they 
can bind to the P-Y on the receptor and JAK kinases in order to preclude binding of 
additional signaling molecules and induce the proteolytic destruction. Phosphatases 
act removing the P-Y sites on the receptor and signaling molecules. Moreover, c-Mpl 
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can be removed from the cell surface after TPO-binding in a clathrin-mediated 
process. The receptor, in fact, bears two YRRL sequences necessary for the 
recognition of this protein as a substrate of the clathrin-mediated endocytosis.  
Glycosylation of c-Mpl appears to play an important role in cell surface expression of 
the receptor. There are four sites of potential N-linked glycosylation: N117, N178, N298 
and N358. In some cases of polycythemia vera, c-Mpl has been found to be 
underglycosylated and surface display of the receptor is decreased 40. In addition, c-
Mpl might go to degradation through the proteasome since it contains two 
intracellular lysines (K) that are potential targets for the ubiquitination (K553, K573) 
37,41.   
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2.3 HEREDITARY THROMBOCYTHEMIA 
 
Hereditary Thrombocythemia (HT) is a familial form of myeloproliferative disease 
(MPD) characterized by sustained proliferation of megakaryocytes and 
overproduction of platelets, which is often clinically indistinguishable from the 
sporadic essential thrombocythemia (ET). Platelets count normally ranges from 100 
to 400 x 109/L 2,42-44. In clinical practice, the term “thrombocytosis” refers to platelets 
counts above 450 x 109/L. Thrombocytosis may be classified into mild (platelets 
counts: 450-700 109/L), moderate (700-900 x 109/L) or severe (>900 x 109/L) 42. 
Thrombocytosis can be considered as primary, if caused by a defect intrinsic to the 
hematopoietic progenitors, or as secondary (or reactive), if consequence of a disease 
that persistently stimulate the otherwise normal magakaryocytopoiesis. Primary 
thrombocytosis includes both acquired (essential thrombocythemia) and hereditary 
form 45. In the first ones, abnormalities are detectable only in cells belonging to the 
hematopoietic system and around 50% of the acquired cases present a gain-of 
function mutation in JAK2 gene (JAK2 V617F) 46-49.   In the hereditary forms genetic 
defects are present in both somatic and germ line cells and are transmitted as a 
hereditary character. None of the hereditary form presents the JAK2 V617F alteration 
45. However, it has been recently reported a germline JAK2 V617I mutation 
associated with hereditary thrombocytosis 50. HT is often a polyclonal disease 
affecting selectively the megakaryocytic lineage, the inheritance is autosomal 
dominant and the penentrance is close to 100% 51. In some case of HT, mutations of 
thrombopoietin or MPL gene are the disease-causing defects (Table1). Up to date, 
four different THPO mutations have been described. All mutations are located in the 
5’UTR region and delete the untranslated open reading frame (uORF). This causes 
increased translation of the THPO mRNA resulting in an overproduction of TPO and 
hence thrombocytosis. THPO mutations that cause HT have not been found in 
patients with sporadic ET 52. Three germ line MLP mutations have been reported so 
far. The MPL-S505N mutation involves the transmembrane domain of MPL inducing 
an autonomous dimerization of the receptor activating the downstream signaling 
pathways in a TPO-independent way 53.  This mutation appears functionally similar to 
MPL-W515K/L acquired mutation reported in some patients with myeloproliferative 
neoplasm (MPN). MPL-K39N is a polymorphism restricted to African Americans. 
About 7% of this population is heterozygous for this mutation. In homozygosity, this 
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mutation causes a severe thrombocytosis 54. The MPL-P106L mutation was first 
described in an Arabic family. The frequency of this alteration is about 6% among 
Arabic individuals. The homozygous state is associated with mild to severe 
thrombocytosis 55. Both these last two mutation involve the CRM1 domain of the 
MPL, most probably affecting the receptor’s ability to bind TPO and resulting in 
reduced clearance of the thrombopoietin and in the over-stimulation of 
megakaryocytopoiesis 45. Thus, in many families with hereditary thrombocythemia 
the disease-causing gene remains unknown. 
 
Involved GENE Molecular 
alteration 
Autosomal 
inheritance 
TPO levels 
THPO G to C mutation in 
the splice donor site 
of intron 3 
Dominant High 
THPO G deletion in 5’UTR Dominant High 
THPO G to T substitution in 
exon 3 
Dominant High 
THPO A to G mutation in 
intron 3 
Dominant High 
MPL S505N Dominant - 
MPL K39N Dominant (low 
penetrance) 
- 
MPL P106L Recessive High 
Table 1: molecular alteration in hereditary thrombocythemia 
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2.4 GENETIC STUDIES FOR THE IDENTIFICATION OF THE DISEASE CAUSING 
GENE 
 
     2.4.1 Linkage analysis 
 
Familial forms of MPD, such as HT, are polyclonal and caused by germ-line 
mutations inherited in the Mendelian way among family members. The use of linkage 
analysis to search for the disease gene has been quite successful in some families 
with HT and with primary familial and congenital polycythemia (PFCP) 52. The 
principle of linkage analysis is simple. The genome differs in several positions for 
different genetic markers, which are DNA sequences that show polymorphism 
(variations in size or sequence) in the population. Thanks to these variants it is 
possible to distinguish the maternal and paternal alleles and in the case of the 
disease gene, the alternative alleles will be the normal allele and the disease allele. 
In this condition the different alleles can be distinguished by looking for occurrences 
of the disease in the pedigree. These studies are based on the fact that 
recombination rarely occurs between two loci that are close to each other on the 
same chromosome. By searching for genetic markers segregating with the disease 
phenotype, the potential disease genes can be identified from their proximity to the 
marker’s location. Any mendelian character that can distinguish the paternal and 
maternal allele in one individual can be used as a genetic marker. However, a good 
genetic marker needs to be sufficiently polymorphic and densely located throughout 
the whole genome (<20cM). The first generation of genetic markers was restriction 
fragment length polymorphism (RFLP). The limitation of RFLPs is that they have only 
two alleles, the restriction site is present or it is absent, and therefore not very 
informative. Construction of dense human genetic maps could be possible with the 
introduction of microsatellite markers. Short tandem repeat polymorphisms (STRs) 
are multiallelic and more informative. STRs can be identified by PCR making the 
linkage analysis fast and easy. Moreover, many compatible sets of microsatellite 
markers have been developed that can cover the whole genome with 400 markers. 
Microsatellite marker analysis can be complemented with the use of single nucleotide 
polymorphism (SNPs). Nowadays, a gene chip technology is available that can 
integrate thousands of SNPs in one single chip and genotype them at once. SNPs 
are bi-allelic markers and less informative than microsatellites. However the large 
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amount of SNPs that can be genotyped in a single chip make them a very powerful 
tool 56.  
Linkage studies rely on statistical evaluation of the evidence in favour of the co-
segregating marker loci with a trait 57. The analysis can be parametric or non-
parametric. Parametric linkage analysis is pedigree-based and defines explicit 
relationship between phenotypic and genetic similarity. This approach is typically 
used for single gene disorders and Mendelian forms of complex disorders. It requires 
a model for the disease, including the mode of inheritance, the disease penetrance 
and the allele frequency. In principle, this type of analysis estimates the 
recombination fraction between two or more loci. Such estimation can be biased if 
the model of inheritance has been mis-specified. Therefore, a non-parametric 
analysis is required when the disease model is unknown. Non-parametric methods 
test for increased sharing among affected individuals and evaluate whether 
segregation at specific location is “not-random”. Specifically, the objective is to show 
increased identical by descendent (IBD) sharing among sets of affected individuals. 
Without making any assumptions about the genetics of the disease, it has been used 
as the main tool for studying common nonmendelian diseases. However 
nonparametric methods decrease the power of mapping, candidate regions defined 
by this method are usually large 58.   
Although powerful for detecting genetic loci in single gene disorder, linkage analysis 
has only limited success in finding genes for multifactorial diseases such as diabetes, 
asthma and heart disease. With the rapid progress of genotyping technology and the 
identification of a constantly increasing number of DNA variants, genetic association 
studies became the preferable for mapping complex diseases.  Genetic association 
approaches assess correlation between genetic variants and trait difference on a 
population scale. Association relies on the retention of adjacent DNA variants over 
many generations. Thus, association studies can be regarded as very large linkage 
analysis of unobserved hypothetical pedigrees. They draw from historic 
recombination so disease-associated regions are very small, including one gene or 
gene fragment. In fact, through subsequent generations, recombination will occur 
and separate the disease mutation from the specific alleles of its original haplotype. 
Still, there are various limitations in these studies dependent on the particular design, 
study aims and analytical framework adopted. Therefore, it is crucial to critically 
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design the approach to use in order to avoid mistakes and maximize the potential to 
identify new components of disease 59.  
 
 
     2.4.2 Characterization of candidate mutation 
 
Identification of genetic variation within a pedigree is quite relevant to study cases of 
familial disease, such as hereditary thrombocytemia. The automated Sanger 
sequencing method, considered as “first-generation” technology, has been replaced 
with newer methods referred to as next-generation sequencing (NGS). These newer 
technologies constitute various strategies that rely on a combination of sample 
preparation, sequencing, genome alignment and assembly methods. NGS platforms 
are very useful for many applications, including the sequencing of targeted region of 
interest. Once an alteration is detected, it is needed to confirm that is a candidate 
mutation. The sequence work-up is summarized in figure 6 (Fig.6). The first step is 
excluding that the alteration is a known polymorphism. The mutation must be present 
in all affected family member of the pedigree and must be absent in at least 100 
normal controls analyzed for the same alteration. When the confirmation step is 
concluded, the relevance of the candidate mutation must be validated with functional 
assays. The first approach could be to predict the impact of the amino acid change 
on protein function with computational program such as Sorting Intolerant From 
Tolerant (SIFT) 60 or PolyPhen-2 61 62. This is only the first screening that must be 
complemented with proper in-vitro and in-vivo assay. The generation of transgenic 
mouse model could be a powerful tool to directly demonstrate the role of this 
mutation for induction of the disease. 
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Fig. 6: sequence work-up 
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3. RESULTS 
 
 
 
 
3.1 FAMILY WITH HEREDITARY THROMBOCYTHEMIA  
 
 
Hereditary Thrombocythemia is reported in 16 family members in five successive 
generations (Fig.1). The inheritance is autosomal dominant with early onset of the 
disease. The pathological phenotype is characterized by persistent elevation of the 
platelet counts ranging from 700 x 109/L to 1200 x 109/L, occasional giant platelets 
with abnormal aggregation, isolated hyperplasia of enlarged megakaryocytes and 
splenomegaly. White blood cell count, hemoglobin level, thrombopoietin and bone 
marrow iron storage are normal in affected patients 63. No mutations were detected in 
MPL and THPO.  
 
 
Fig.1 Pedigree of the family affected by hereditary thrombocythemia. The inheritance is autosomal 
dominant with a high penetrance of the disease. Filled black symbols, affected individuals; open 
symbols, normal individuals; filled grey symbols, not studied; crossed symbols, deceased. 
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3.2 LINKAGE ANALYSIS 
 
Since in the HT family it was expected that a genetic component was responsible for 
the phenotype, parametric linkage analysis was used to detect the chromosomal 
location of the disease-gene. This has been the traditional approach for mapping 
Mendelian disease since the 1970’s. To determine if there was significant evidence 
for linkage, LOD scores were calculated. LOD stands for Log of the ODds. A LOD 
score greater than 3 gives the evidence of linkage with 5% chance of error. Linkage 
can be rejected if the LOD score is lower than -2. Values between -2 and 3 are 
inconclusive 64. 
 
Fig 2 Segregation of microsatellite markers. Microsatellite markers are positioned according to 
physical distance (measured in Mb). Co-segregating microsatellites are reported in red. The disease 
allele is marked in pink. Data reported in blue are the ones I generated. 
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A former PhD student, Liu Kun, performed genome-wide linkage analysis of 20 family 
members (10 affected and 10 unaffected) with microsatellite markers 65. When I 
joined the lab, I filled some gaps of the analysis and I characterized three additional 
patients EY6, EY22 and EY23 (Fig.2). From this segregation analysis the haplotypes 
were built as shown in figure 3. A co-segregating region shared between the 12 
affected family members and not shared by the non-affected family members was 
found on chromosome 9p with the highest LOD score of 4.3 at theta = 0 (Fig.3). The 
co-segregating region found was approximately 4 megabase (Mb) in size. 
 
 
Fig.3 Haplotype analysis of nine microsatellite markers located on chromosome 9 from marker 
D9S1856 to marker D9S123. Microsatellite markers are positioned according to physical distance 
(measured in Mb). Individuals with HT are indicated by filled symbols and unaffected individuals by 
open symbols. Haplotypes for these markers are shown with pink boxes.  
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To further investigate the inherited traits in the family a SNP chip array was 
performed on 14 family members: 7 affected and 7 unaffected. The major part of the 
data were obtained from the former PhD student 65, after I took over the project the 
SNP analysis was remade with the addition of a new patient. The data obtained 
confirmed a co-segregating region on chromosome 9p of 4 Mb (positions: 119.9-
124.0, NCBI36/hg18 assembly) with the highest LOD score of 3 at theta=0 (Fig.4). 
 
 
Fig. 4 Linkage analysis of hereditary thrombocythemia for Affimetrix 50K SNP array Xba240 is shown 
for all chromosomes. 14 family members (7 affected and 7 unaffected) were included in the analysis. 
Homozygous SNPs are shown in red or blue, heterozygous SNPs are shown in yellow. The 
maximum LOD peak was 3 (θ=0) at chromosome 9 assuming an autosomal dominant model. LOD 
score of 3 is indicated by a red line. 
 
According to this data, the co-segregating region on chromosome 9p was defined 
from position 113 Mb to 124 Mb (hg18, UCSC). This region contains 93 genes listed 
in Table1.   
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STR marker Gene ID Gene Name Position  
(Mb) 
D9S1856 
OR2K2 
Olfactory receptor, family 2, subfamily K, 
member 2 
113.8 
 KIAA0368 KIAA1958  
 ZNF483 zinc finger protein 618  
 PTGR1 Prostaglandin reductase 1  
 
LRRC37A5P 
Leucine-rich repeat-containing 37 member 
A5 pseudogene 
 
 DNAJC25-GNG10 DNAJC25-GNG10  
 
DNAJC25 
DnaJ (Hsp40) homolog, subfamily C , 
member 25 
 
 
GNG10 
Guanine nucleotide binding protein (G 
protein), gamma 10 
 
 C9orf84 Chromosome 9 open reading frame 84  
 UGCG UDP-glucose ceramide glucosyltransferase  
 SUSD1 Sushi domain containing 1  
 PTBP3 Polypyrimidine tract binding protein 3  
 HSDL2 Hydroxysteroid dehydrogenase like 2  
 KIAA1958 KIAA1958  
 INIP SSB-interacting protein 1  
 SNX30 Sorting nexin family member 30  
 SLC46A2 Solute carrier family 46, member 2  
 ZNF883 Zinc finger protein 883  
 ZFP37 Zinc finger protein 37  
 
FAM225B 
Family with sequence similarity 225, 
member B 
 
 
FAM225A 
Family with sequence similarity 225, 
member A 
 
 
SLC31A2 
Solute carrier family 31 (copper 
transporters), member 2 
 
 FKBP15 FK506 binding protein 15  
 
SLC31A1 
Solute carrier family 31 (copper 
transporters) 
 
 CDC26 Cell division cycle 26 homolog  
 
PRPF4 
PRP4 pre-mRNA processing factor 4 
homolog 
 
 RNF183 Ring finger protein 183  
 WDR31 WD repeat domain 31  
 BSPRY B-box and SPRY domain containing  
 
HDHD3 
Haloacid dehalogenase-like hydrolase 
domain containing 3 
 
 ALAD Aminolevulinate dehydratase  
 
POLE3 
Polymerase (DNA directed), epsilon 3, 
accessory subunit 
 
 C9orf43 chromosome 9 open reading frame 43  
D9S289 RGS3 regulator of G-protein signaling 3 115.3 
 ZNF618 zinc finger protein 618  
 AMBP alpha-1-microglobulin/bikunin precursor  
D9S1824 KIF12 kinesin family member 12 115.8 
 COL27A1 collagen, type XXVII, alpha 1  
 ORM1 orosomucoid 1  
 ORM2 orosomucoid 2  
 AKNA AT-hook transcription factor  
 DFNB31 deafness, autosomal recessive 31  
 
ATP6V1G1 
ATPase, H+ transporting, lysosomal 13kDa, 
V1 subunit G1 
 
 C9orf91 chromosome 9 open reading frame 91  
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TNFSF15 
tumor necrosis factor (ligand) 
superfamily, member 15 
 
 
TNFSF8 
tumor necrosis factor (ligand) superfamily, 
member 8 
 
D9S1776 TNC tenascin C 116.9 
 
PAPPA 
pregnancy-associated plasma protein A, 
pappalysin  
 
D9S170 ASTN2 astrotactin 2 118.0 
 TRIM32 tripartite motif containing 32  
 TLR4 toll-like receptor 4  
D9S934 DBC1 deleted in bladder cancer 1 120.0 
D9S195 
CDK5RAP2 
CDK5 regulatory subunit associated protein 
2 
121.0 
 MEGF9 Multiple EGF-like-domains 9  
 FBXW2 F-box and WD repeat domain containing 2  
 
PSMD5 
Proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 5 
 
 PHF19 PHD finger protein 19  
 TRAF1 TNF receptor-associated factor 1  
 C5 Complement component 5  
 CEP110 Centriolin  
 RAB14 Member RAS oncogene family  
 GSN Gelsolin  
 STOM Stomatin  
 
GGTA1P 
Glycoprotein, alpha-galactosyltransferase 1 
pseudogene 
 
 DAB2IP DAB2 interacting protein  
 
TTLL11 
Tubulin tyrosine ligase-like family, member 
11 
 
 
NDUFA8 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex 8 
 
 MORN5 MORN repeat containing 5  
 LHX6 LIM homeobox 6  
 RBM18 RNA binding motif protein 18  
 MRRF Mitochondrial ribosome recycling factor  
 PTGS1 Prostaglandin-endoperoxide synthase 1  
 
OR1J1 
olfactory receptor, family 1, subfamily J, 
member 1 
 
 
OR1J2 
olfactory receptor, family 1, subfamily J, 
member 2 
 
 
OR1J4 
olfactory receptor, family 1, subfamily J, 
member 4 
 
 
OR1N1 
olfactory receptor, family 1, subfamily N, 
member 1 
 
 
OR1N2 
olfactory receptor, family 1, subfamily N, 
member 2 
 
 
OR1L8 
olfactory receptor, family 1, subfamily L, 
member 8 
 
 
OR1Q1 
olfactory receptor, family 1, subfamily Q, 
member 1 
 
 
OR1B1 
olfactory receptor, family 1, subfamily B, 
member 1 
 
 
OR1L1 
olfactory receptor, family 1, subfamily L, 
member 1 
 
 
OR1L3 
olfactory receptor, family 1, subfamily L, 
member 3 
 
 
OR1L4 
olfactory receptor, family 1, subfamily L, 
member 4 
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OR1L6 
olfactory receptor, family 1, subfamily L, 
member 6 
 
 
OR5C1 
olfactory receptor, family 5, subfamily C, 
member 1 
 
 
OR1K1 
olfactory receptor, family 1, subfamily K, 
member 1 
 
D9S1682 PDCL phosducin-like 123.8 
 RC3H2 ring finger and CCCH-type domains 2  
 ZBTB6 zinc finger and BTB domain containing 6  
 ZBTB26 zinc finger and BTB domain containing 26  
 RABGAP1 RAB GTPase activating protein 1  
 GPR21 G protein-coupled receptor 21  
D9S123 STRBP spermatid perinuclear RNA binding protein 124.0 
 
Tab 1 List of the genes present in the co-segregating region. STR, short tandem repeat. 
Microsatellites markers in yellow represent the maximal shared region. Microsatellites markers in red 
represent the minimal co-segregating region.  
 
 
3.3 NEXT GENERATION SEQUENCING (NGS) 
 
To sequence the co-segregating region of interest, a next generation sequencing 
based on “target-enrichment” was performed. This “target-enrichment” method allows 
the selective capture of genomic fragments using RNA baits with complementary 
sequences to the DNA regions of interest. The enrichment of the DNA was 
performed with two different platforms (Fig 5).  In the Nimblegen platform 20 g of 
genomic DNA are fragmented and then attached to 454-adaptor without PCR 
amplification before the enrichment step. The Agilent platform, instead, allows the 
enrichment of smaller quantity of genomic DNA (1-5 g), which is amplified by a PCR 
step after the fragmentation and adapter-ligation steps. The enriched exonic region 
on chromosome 9 had a total size of 450 kb and it covered around 900 exons 
(including UTR and intron-exon boundaries).  
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Fig 5 Platforms used for the enrichment step. 
 
The sequencing step was performed using both Illumina and Roche 454 
technologies. The statistics of this step are summarized in Table 2. The sequence 
capture followed by NGS was very efficient and only 11 exons were not covered. 
Five of these exons were successfully analyzed by capillary sequencing and the 
remaining 6 could not be sequenced probably due to a high GC content.  
 
 Illumina 
(Nimblegen) 
Illumina 
(Agilent) 
454  
(Nimblegen Titanium) 
Reads 14,798,154 
(two PE seq) 
 
5,058,820 
(one SE seq) 
 
613,227 
(1/2 plate) 
bp 497,487,433 
 
186,988,134 
 
218,899,568 
 
% of exons  
(> 10 coverage) 
96.7 % 94.8 % 95,3 % 
 
Average 
Coverage 
114 45 46 
 
Tab 2 Statistics about the coverage of the sequencing step. PE seq, pair-end sequencing; SE seq, 
single end sequencing. 
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3.4 SEQUENCING DATA ANALYSIS AND VALIDATION 
 
 
3.4.1 Filtering and analysis of NGS data in the family affected by HT 
 
The next generation sequencing was performed on two patients: EY1 and EY11. 
These patients were chosen for sequencing since they are located far apart in the 
pedigree, thus decreasing the amount of regions shared by chance. In both patients, 
around 1200 sequence alterations were found. These alterations were filtered out 
according to the fact that they were not described as known polymorphisms, they 
alter the coding region of a gene causing a nonsynonymous amino acid change and 
they are common heterozygous alterations. Only five SNPs matched these criteria 
and they were confirmed by capillary sequencing. Among these polymorphisms only 
two were confirmed in all the 12 affected family members (Tab 3).  
 
 
 
Tab 3 Filtering of the next generation sequencing data. 
 
 
The first SNP was found in the gene centriolin (CEP110) causing a leucine to serine 
change at position 954 (L954S) and the second one in the gene gelsolin (GSN) 
causing a glycine to cysteine change at position 254 (G254C). In order to exclude 
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that these alterations are rare polymorphisms, a screening of the 2 SNPs was 
performed in normal controls (NC). The alteration L954S in CEP110 was found in 7 
NC on 307 screened, suggesting that it is a rare polymorphism with an allele 
frequency in the population of 1.1%. On the contrary, the alteration G254C in gelsolin 
was not detected in 443 normal controls screened and can be considered as a 
candidate mutation rather than a polymorphism.  
 
3.4.2 Screening of GSN mutation in HT families and sporadic ET patients 
 
Since GSN was the only candidate gene fitting all the criteria, 13 other families 
affected by Hereditary Thrombocythemia and 240 sporadic MPD patients were 
screened for mutations in this gene. The screening of the 13 families was done by 
capillary sequencing and it revealed the presence of sequence alterations in 3 of 
them. In one family, 2 SNPs were found in exon 13 (T563S) and exon 14 (T616M). 
These alterations were homozygous in the father (the propositus) and heterozygous 
in the two children. Another pedigree showed a sequence alteration in the intron 
between exon 6 and 7. However, all these variations had already been reported as 
known SNPs. In another family, a SNP was found in exon 16 (T695M), which was not 
present in all the affected family members. The cohort of 240 sporadic MPD patients 
was analyzed by next generation sequencing. The screening identified 7 alterations 
(Fig. 7). Among these, only 3 alterations were confirmed by capillary sequencing: 
V179M, V460M and V606M. The first two were recurrent alteration because they 
were observed in two different ET patients, whereas the third one was present only in 
one patient. These SNPs have been already reported in the common SNP database 
with a frequency in the population lower than 1%. In some patients, the alteration 
was found to be of germline origin (Tab 4). Interestingly, the variation V179M can be 
present in a patient as a germline mutation or can occur as a somatic event.  
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Fig. 6 Position of the 7 different alterations found in sporadic ET patients by NGS. In order: V179M, 
G254C, G264S, P278Q, S412I, V460M, V606M. 
 
Patient 
(diagnosis) 
JAK2 
V617F 
status 
Alteration  
(granulocytic 
DNA) 
Presence  
(germline 
DNA) 
SNP frequency 
p060 (ET) - V179M YES 0.003708 
 
p163 (ET) - V179M NO  
p273 (ET) 97% 
 
V460M Not 
available 
0.000659 
p325 (PMF) - V460M YES  
p291 (PV) 87% 
 
V606M YES 0.000660 
 
 
Tab 4 Alterations found by next generation sequencing and confirmed by capillary sequencing in 
sporadic patients. Sequencing was performed on granulocytes DNA and germline DNA. ET, 
essential thrombocytemia; PV, Polycythemia vera; PMF, primary myelofibrosis. 
 
3.4.3 Characterization of the GSN variations found 
 
In order to predict if the amino acid substitution can potentially affect protein function, 
computational predictions were performed with two different software: SIFT (Sorting 
Intolerant From Tolerant) and PolyPhen-2. SIFT uses sequence homology to predict 
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whether an amino acid change will affect protein function and potentially alter the 
phenotype. This algorithm considers the position at which the change occurred and 
the type of amino acid change. SIFT predicts substitutions with score less than 0.05 
as deleterious. Polyphen-2 uses eight sequence-based and three structure-based 
predictive features to evaluate the impact of the amino acid change. The SNP 
alteration in GSN gene were analyzed with both software and the results are 
summarized is Table 5. Interestingly, the alteration G254C identified in the HT family 
is predicted to alter the protein function with both algorithms and with the most 
significant score values. Another interesting alteration is V179M, which is predicted to 
be probably damaging with both software, even if the score values are less 
impressive than the ones of G254C. 
 
Mutation SIFT PholyPhen 
G254C 0.00  
V179M 0.04  
V460M 0.01  
V606M 0.22   
 
Tab 5 Computational predictions of the different amino acid change in GSN gene with the SIFT and 
PholyPhen software. 
  
 
Computational analysis must be complemented with structural analysis. Using the 
Consurf server is possible to estimate the evolutionary conservation of amino acid 
positions in a protein molecule based on the phylogenetic relations between 
homologous sequences and to visualize the desired position in the structure of the 
molecule. The degree to which an amino acid position is evolutionarily conserved is 
strongly dependent on its structural and functional importance; rapidly evolving 
positions are variable while slowly evolving positions are conserved. Usually, the 
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functionally important regions of the protein are highly conserved. The crystal 
structure of gelsolin domains G1-G3 bound to actin was analysed with the Consurf 
server. Gelsolin was visualized using a space-filled model and actin with sticks 
structure. The mutation G254C and the polymorphism V179M were localized and 
marked with yellow haloes. Interestingly, the positions of both alterations are 
conserved. The position 254 has a conservation score of 9 (bounds of the confidence 
interval 9-9) with few residues variety (S,A,G) and the position 179 has a 
conservation score of 8 (bounds of the confidence interval 8-7) with six residues 
variety (A,Q,T,P,I,V). Both the variations are located at the interface with actin.  
  
 
 
Fig 7 Crystal structure of human GSN domains G1-G3 bound to actin analyzed with Consurf server. 
The 3D structure of gelsolin bound to actin is presented using a space-filled model. The amino acids 
are colored by their conservation grades using the color-coding bar, with turquoise-through-maroon 
indicating variable-through-conserved. Positions, for which the inferred conservation level was 
assigned with low confidence, are marked with light yellow. Amino acid of the variations G254C and 
V179M are marked with yellow haloes.  
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3.4.4 Gelsolin expression in sporadic ET patients 
 
In sporadic patients affected by essential thrombocytosis, where the disease is not 
caused by an inherited mutation, it could be possible that alterations in gelsolin gene 
could affect not only the sequence itself, but also the expression level. Therefore in 
addition to the sequencing data, GSN expression in platelets of ET patients was 
investigated. For the analysis, 57 sporadic ET patients were included and subdivided 
according to their JAK2 V617F status. Fifteen normal controls were used as 
reference in the study. GSN expression in JAK2 V617F negative and JAK2 V617F 
positive ET patients was not significantly different from the normal control (Fig. 8a). 
Also patients EY11 (affected) and EY18 (unaffected) were included in the analysis. 
Interestingly, patient EY11 had a higher GSN expression (value 10.98) compared to 
patient EY18 (value 0.08). Unfortunately, it was not possible to include more EY 
patients in the analysis because of the difficulties to get viable material from the 
patients who live in the United States.  No correlation between GSN expression and 
JAK2 V617F allele burden was found (Fig. 8b). 
 
 
Fig 8 (a) GSN expression in platelets of sporadic ET patients relative to the housekeeping gene 
RPL19. 15 normal controls, 19 sporadic ET patients JAK2 V617F negative, 38 sporadic ET patients 
JAK2 V617F positive have been included in the study. (b) Correlation between GSN expression and 
JAK2 V617F allelic burden.  
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3.5 GSN: a potential candidate gene 
 
3.5.1 Structural analysis of the mutation G254C found in the HT family 
 
Gelsolin is a Ca2+ regulated actin filament severing, capping and nucleating protein. It 
is involved in the regulation of cell structure and metabolism. Interestingly, it has a 
key-role in regulating apoptosis and platelet modulation. Gelsolin is composed of six 
domains named (from the N-terminus) as G1-G6. Each domain contains a Ca2+-
binding site. A unique feature of GSN is that apart from the cytoplasmic protein found 
in most cell types, a secreted plasma form can be generated by alternative splicing in 
muscle cells. Cytoplasmic as well as secreted gelsolin are the most potent actin 
filament severing proteins identified to date 66. From the analysis of the 
crystallography structure of GSN (domains G1-G3) and actin, it is possible to identify 
the position of the alteration G254C (Fig. 9a). GSN protein is marked in violet and 
actin in green. The glycine at position 254, marked in yellow, is localized at the 
interphase with actin molecule. The distance between the C of the amino acid 
glycine of gelsolin and the C of the serine on actin is 4.2 Angstrom (Fig 9b). The 
change of glycine to a cysteine (G254C) in the position 254 can potentially affect the 
interaction between the two molecules.  
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Fig 9 (a) Crystal structure of gelsolin protein domains G1-G3 (violet) bound to a molecule of 
actin (green). (b) Zoom on the glycine (yellow) at position 254 of the gelsolin protein. 
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3.5.2 Caspase-3 cleavage of GSN protein 
 
Apoptosis is a fundamental physiological process required for the development and 
homeostasis of different tissues. Caspase-3, an important effector of apoptosis, 
cleaves gelsolin in two fragments: N-terminal gelsolin and C-terminal gelsolin. The N-
terminal GSN fragment not only severes actin in a Ca2+-independent manner, but 
also contributes to morphological changes of apoptosis. De Botton et al found active 
forms of caspase-3 and caspase-9 in cultured human megakaryocytes and observed 
cleavage of substrates such as gelsolin in cells that had begun to shed platelets 18. 
To investigate whether the presence of the mutation G254C could affect the 
caspase-3 activity, an in vitro cleavage assay was performed. This test showed that 
GSN G254C is cleaved more efficiently compared to GSN wild type. The C-terminal 
fragment of GSN G254C was visible after 30 minutes of caspase-3 incubation, 
whereas for the wild type GSN the fragment appeared only after one hour (Fig 10).  
 
 
Fig 10 Time curve of caspase cleavage assay. W: human gelsolin cytoplasmic wild type, M: 
human gelsolin cytoplasmic G254C. Actin: loading control. 
 
3.5.3 Gelsolin translocation into the nucleus 
 
Gelsolin can translocate into the nucleus and participate in signal transduction. 
Caspase-3 cleavage products or full-length gelsolin can act as inhibitory or 
stimulatory factors in apoptosis. To investigate whether the alteration G254C can 
influence the ability of GSN to translocate into the nucleus, nuclear and cytoplasmic 
fractions of gelsolin stable transfected cell line were analyzed by western blot.  No 
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alterations in GSN translocation were observed between cell line stable transfected 
with the wild type gene and with the altered gene (Fig 11). 
 
 
Fig 11 Gelsolin translocation into the nucleus. Hek: HEK 293T cells (negative control), W: HEK 
293T cells stable transfected with human gelsolin cytoplasmic wild type, M: HEK 293T cells stable 
transfected with human gelsolin cytoplasmic G254C. Sam68: nuclear marker, Tubulin: cytoplasmic 
marker. 
 
3.5.4 Platelets biogenesis assay 
 
The megakaryoblastic cell line DAMI is derived from the peripheral blood of a patient 
with megakaryoblastic leukemia. These cells can be induced to differentiate along 
the megakaryocytic lineage when stimulated with phorbol myristate acetate (PMA) 
and TPO. After differentiation, DAMI cells can release platelets-like particles in the 
culture supernatant 67. DAMI cell line stably transfected with wild type GSN and GSN 
G254C were established and used for the platelets biogenesis assay. During the 
PMA and TPO stimulation, DAMI cells stopped to proliferate and started to increase 
their adherence to the plastic culture plates and to spread (Fig 12a). After 7 days of 
stimulation, DAMI cells started to release platelets-like particles in the supernatant 
and they could be quantified and identified with the markers CD61 and CD41 by 
FACS. DAMI cells expressing the mutant GSN (G254C) released higher amounts of 
CD61+CD41+ particles in the culture supernatant compared to untransfected DAMI 
cells and DAMI cells expressing wild type GSN (Fig 12b).  
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Fig 12 (a) DAMI cell line differentiates along megakaryocytic lineage upon stimulation with PMA 
(1uM) and TPO (10 ng/ml). Cells stop proliferating and start to adhere to the plastic culture dish. 
(b) PLTs-like particles released in the culture supernatant. DAMI, cell line not transfected; DAMI 
WT GSN, DAMI cells stable transfected with wild type GSN; DAMI MT GSN, DAMI cells stable 
transfected with mutant GSN. Results were compared with 2way ANOVA (***p<0.001). 
  
 
3.6 ANIMAL MODEL 
 
3.6.1 Transplantation with bone marrow cells transduced with GSN 
 
To study the potential in vivo role of GSN G254C in the pathogenesis of HT, lethally 
irradiated recipient mice were transplanted with BM cells transduced with retrovirus 
expressing human cytoplasmic mutant GSN-IRES-GFP. As a control, a virus 
overexpressing human cytoplasmic wild type GSN-IRES-GFP was used. In each 
group, 4 recipient mice were transplanted with 15% GFP positive BM cells. Mice 
were monitored 30 days after transplant and followed for 8 months. At each time 
point, chimerism and blood counts were investigated. The chimerism was calculated 
as the percentage of GFP positive cells for different cell lineages: erythrocytes 
(Ter119+), platelets (CD61+), granulocytes (Gr-1+) and monocytes (Mac1+). The 
percentage of GFP positive cells in each mouse showed a high variability. The 
mouse MT2, with stable GFP positive platelets close to 90 % from day 60 post-
transplant, showed a mild increase in platelet counts in the group of animals 
transplanted with BM cells transduced with human cytoplasmic mutant GSN-IRES-
GFP whereas the other animal from this group exhibited entirely normal blood counts 
(Fig.13). No mice from the control group had variations in platelet counts and any 
other blood parameters.  
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Fig. 13 (a) Platelet counts in the group of mice transplanted with human cytoplasmic wild type GSN-
IRES-GFP. (b) Percentage of GFP positive circulating platelets in mice transplanted with human 
cytoplasmic wild type GSN-IRES-GFP. Platelet chimerisms were measured according to the 
double-positive population CD61+/GFP+. (c) Platelets count in the group of mice transplanted with 
human cytoplasmic mutant GSN-IRES-GFP. (b) Percentage of GFP positive circulating platelets in 
mice transplanted with human cytoplasmic mutant GSN-IRES-GFP. Platelet chimerisms were 
measured according to the double-positive population CD61+/GFP+. 
  
GSN expression was analyzed in peripheral blood (120 days after transplant) and in 
platelets (210 days after transplant) by real time PCR with primers human specific 
(Fig. 14). Human gelsolin expression in each mouse was quite variable as expected 
from the GFP signal. The mouse MT2 showed a high relative human gelsolin 
expression in peripheral blood and platelets. This data correlated with the high GFP 
chimerism observed by FACS analysis. 
 
Fig. 14 (a) Human gelsolin expression (red bar) and mouse gelsolin expression (blue bar) for each 
mouse in peripheral blood 120 days after transplant. (b) Human gelsolin expression (red bar) and 
mouse gelsolin expression (blue bar) in mouse platelets at 210 days after transplant. 
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Cytoplasmic gelsolin can be involved in apoptosis regulation. To assess whether 
G254C GSN can induce a longer platelets survival in transplanted mice, platelets 
clearance was analyzed in vivo. By tracking the survival of biotin-labeled platelets in 
vivo at different time point, it was possible to analyze the life span of GFP positive 
and GFP negative platelets in mice (Fig. 15). No differences in platelets life span 
were observed between GFP positive and negative platelets in both groups of mice.   
 
 
Fig. 15 (a) Life span of biotinylated platelets in mice group transplanted with human cytoplasmic wild 
type GSN-IRES-GFP. (b) Life span of biotinylated platelets in mice group transplanted with human 
cytoplasmic wild type GSN-IRES-GFP. Peripheral blood samples were taken at 4, 24, 48, 72 and 96 
hours after injection with NHS-biotin. 
 
3.6.2 Generation of GSN G254C transgenic mice 
 
To establish a more stable animal model expressing both cytoplasmic and plasma 
gelsolin, BAC-transgenic mice that express the human GSN-G254C driven by the 
endogenous human GSN promoter were generated. The 140-kb BAC clone 
contained 70 kb of GSN 5′-upstream region that does not include other known genes, 
as well as exons 1-17 and a part of intron 17 of the human GSN gene. Using 
homologous recombination in bacteria, the missing part of intron 17, exon 18 and 2.4 
kb of 3’-downstream region were added. The fragment used for homologous 
recombination was excised from the BAC clone RP11-269G20 with BglII and XbaI 
digestion (Fig. 16). The insertion of the mutation was performed with a BAC 
recombineering approach using galK selection cassette. This targeting step 
introduced the G to T transversion at the desired position of GSN (Fig. 17).  
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Fig.16 Transgenic construct. BAC clone CTD2218E19 was modified by the addition of the last exon 
and 3’ UTR sequence of GSN. Homolougus recombination was induced with the excised fragment 
cut with BglII and XbaI from BAC clone RP11-269G20.  
 
The repaired BAC clone CTD-2218E19 was linearized with the unique enzyme cutter 
PmeI and microinjected into oocytes from inbred C57BL/6 mice. Oocyte injection of 
this modified BAC construct, yielded 5 transgenic lines in the inbred C57BL/6 
background named from G1 to G5. 
 
 
Fig. 17 Insertion of the G to T transversion at the desired position of GSN gene. 
 
To verify that the repair of the BAC clone at the 3’ end did not affect the correct 
transcription of the transgene, the integrity of the human gelsolin messenger RNA 
was checked in each founder. A PCR reaction was designed using two different 
human specific primer sets annealing in the middle and at the end of the transcript. 
Amplification was obtained with both primer sets showing that the splicing process 
occured correctly and therefore the human transgene was fully transcribed in mice 
(Fig.18).  
 
Results 
 43 
 
Fig.18 Amplification of the middle part of human gelsolin transcript (region between exon 6 and 
exon 8/9) and the last part of the transcript (region between exon 17 and exon 18). Primers were 
designed to be human specific and to not cross-react with the mouse endogenous GSN gene. 
 
The 5 transgenic lines had different transgene copies as well as human GSN 
expression (Fig.19). The transgene was not passed to the progeny in the G1 line, G2 
and G3 founders had a too low copy number, G4 founder was sterile, while G5 
founder bred efficiently with a very high transgene expression.  
 
 
Fig.19 Transgene copy number and mRNA expression. (a) Transgene copy number per mouse 
genome. The numbers were assessed in the “Absolute Quantification” setup with standard curves 
made from human genomic DNA isolated from a normal control. (b) Relative expression of human 
gelsolin (hGSN). Real-time PCR was performed with primers specific for the human GSN 
transgene. The numbers represent relative expression values calculated by the ΔCT method after 
normalization to the mRNA of mouse RPL19 (c) Human/mouse GSN mRNA ratio. Each GSN primer 
pair was tested to have the same efficiency. Therefore, ratios of human and mouse GSN were 
assessed in the “Relative quantification” setup using the 2
-CT method. 
  
The difference in gelsolin expression between G3 and G5 transgenic line was evident 
also in the platelets lysates isolated from the first progeny derived from the two 
different founders (Fig.20).  G5 mice express high quantity of human gelsolin 
compared to wild type mice either C57BL/6 or G5 wild type littermate. 
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Fig. 20 GSN protein in platelets lysate from the first progeny of G5 (G5: F1mice tg+) and G3 
transgenic line (G3: F1mice tg+). A wild type C57BL/6J mouse (B6) and a G5 wild type littermate 
(G5: F1 tg-) were included in the blot as reference.  Actin was used as loading control. 
 
Transgenic mice derived from G3 strain did not show any abnormalities in different 
blood parameters as expected from the low expression of the transgene (Fig. 21a). 
Therefore the analysis of this strain was stopped at week 22. The G5 derived mice, 
instead, developed a mild phenotype showing a tendency to elevated platelet 
counts compared to their wild type littermates (Fig. 21b). The platelet counts 
were found to be significantly higher in G5 transgenic mice compared to wild 
type littermates (Mann-Whitney test, P = 0.004). No other alterations were 
observed in blood counts in these mice.  
 
 
Fig 21 Time course of platelet counts in transgenic and control mice. Platelets counts of mice at 7 
weeks, 12 weeks, 22 weeks and 27 weeks of age are shown. Black symbols, control mice; blue 
symbols, transgenic mice. Physiological ranges are indicated with a gray box.  (a) G3 transgenic 
mice, (b) G5 transgenic mice. Results were compared with Mann-Whitney test (**p=0.004) 
 
Expression of human gelsolin in G5 transgenic mice was consistent, even if some 
variations were observed in different mice (Fig 22a). Also the expression of 
endogenous gelsolin was variable within the mice. Therefore the ratio between 
human GSN and mouse GSN did not correlate with the expression of the transgene 
(Fig 22b).  
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Fig 22 (a) Human transgene expression in whole blood from 6 mice of G5 strain. (b) Human/mouse 
GSN mRNA ratio. 
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4. DISCUSSION 
 
 
 
 
My PhD studies focused on a large US family affected by hereditary 
thrombocythemia. The patients present with persistent elevation of platelet counts, 
occasional giant platelets with abnormal aggregation, isolated hyperplasia of 
enlarged megakaryocytes and splenomegaly. So far, HT has been described as a 
rare benign disorder possibly caused by mutations in the THPO or the c-Mpl receptor 
genes. Interestingly, in the pedigree studied no alterations were described in these 
two genes. Therefore, the aim of my work was to identify new germ line mutations 
causing HT, which can be also relevant in understanding MPD pathogenesis and 
eventually represent a new target for drug development. Using linkage analysis and 
subsequent targeted next generation sequencing, a novel candidate mutation in 
gelsolin gene (GSN) was discovered in the affected family members. This alteration 
affects the position 254 of the protein causing a major amino acid change from 
glycine to cysteine, thus altering a highly conserved position of the protein. Structural 
analysis revealed that the mutant position is at the interface with actin and the 
distance between the C of the glycine on GSN and the C of the serine on actin is 
only 4.2 Angstrom. The substitution of a glycine with a cysteine at this position can 
easily influence the interaction between the two molecules. In addition, gelsolin is 
abundant in platelets and therefore an interesting candidate gene. Even though the 
gelsolin superfamily proteins are mainly involved in the regulation of actin dynamics, 
they can be multifunctional. Gelsolin, for example, can be involved in apoptosis 
regulation, modulation of platelets, signal transduction and transcriptional activation 
66. To functionally characterize the GSN mutation, in vitro and in vivo studies have 
been performed. DAMI cell line can differentiate into megakaryocytic lineage when 
stimulated with PMA and TPO providing a good system to evaluate cell maturation 
and platelets production. In my experiment, DAMI cells overexpressing GSN G254C 
released more platelet-like particles in the supernatant compared to DAMI 
overexpressing wild type GSN. The in vivo role of the mutation was investigated with 
the generation of BAC transgenic mice expressing the human GSN-G254C. These 
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mice showed a mild tendency to thrombocytosis compared to their wild type 
littermates.    
 
Up to date, the only mutation reported in gelsolin gene was found to be the cause of 
the familial amyloidosis of Finnish type (FAF). This mutation causes an amino acid 
substitution of aspartic acid at residue 187 by either asparagine or tyrosine (in a 
danish FAF family) creating a conformation that predisposes GSN to proteolysis. This 
aberrant cleavage generates the FAF amyloid precursor fragment of 68 kDa. Further 
cleavage at position 244 is required for the generation of FAF amyloid protein 68. A 
transgenic mouse model accurately recapitulates the proteolytic cascade that yields 
the 8- and 5-kDa amyloidogenic peptides putatively causing FAF. Notably, the 
amyloidogenesis is restricted to the muscle tissues where D187N gelsolin is 
synthesized 69. However, so far no mutation in gelsolin have been described in 
hematological disorders.  
 
Even though there is no evidence showing gelsolin involvement in thrombocytosis, it 
is likely that it can play a role in the disease by influencing the apoptotic processes in 
platelets biogenesis and/or favoring the platelets release. The role of apoptosis in the 
megakaryocyte lineage is quite intriguing. Megakaryocytes presumably need to 
prevent the activation of the apoptotic machinery in order to survive and produce 
platelets. Various insults, such as chemotherapy and autoantibodies, have been 
suggested to induce apoptotic death of megakaryocytes and progenitors. 
Conversely, apoptotic processes have been implicated in megakaryocyte 
development and platelet production. Since the initial observation that platelets 
release from megakaryocytes resembles the onset of apoptosis 14, an increasing 
body of evidence suggested that platelets shedding is an apoptotic process. It is 
clear that megakaryocytes possess both an intrinsic and an extrinsic apoptosis 
pathway. However, the control of the apoptosis and its role in MK and platelets 
biogenesis remain to be established. On the contrary, it is well-founded that platelets 
possess an intrinsic apoptosis pathway and can undergo apoptosis 70 71. Bcl-XL and 
Bak are the major components of a “molecular clock” that determines platelets life 
span. Degradation of Bcl-XL triggers Bak-mediated apoptosis and clearance from 
circulation 15. Interestingly, gelsolin is a substrate of caspase-3 and activated forms of 
caspase-3 were detected in maturing megakaryocytes 18. Caspase-3 cleaves gelsolin 
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between residue Asp352 and Gly353 resulting in the generation of two fragments: N-
terminal GSN and C-terminal GSN. Deoxyribonuclease (DNase I) is a key enzyme 
involved in the DNA degradation process occurring in apoptosis. Gelsolin-actin-
DNase I form a ternary complex sequestering the enzyme and therefore showing an 
anti-apoptotic function. N-terminal gelsolin can competitively bind to actin causing the 
release of DNase I from actin to enhance apoptotic activity. On the contrary, the C-
terminal GSN is anti-apoptotic and has a function similar to Bcl-XL, the major 
regulator of platelets survival 66. In my studies, the in vitro caspase-3 cleavage assay 
showed a more efficient cleavage of mutant gelsolin compared to the wild type. Since 
proplatelets formation is regulated by caspase activation and GSN cleavage is a 
hallmark of maturing MKs, the mutation G254C could potentially lead to a more 
efficient proplatelets formation by enhancing caspase-3 gelsolin cleavage. In 
addition, it could also be postulated that in the cytoplasm of platelets expressing the 
mutant GSN there is a higher amount of N-terminal GSN and C-terminal GSN. 
Considering that N-terminal GSN function is based on its capacity to bind actin and 
this binding might be altered by the mutation (as shown from the structural analysis), 
it is possible that the anti-apoptotic function of C-terminal GSN prevails the one of N-
terminal GSN. According to this model, platelets half-life should be increased in 
patients expressing mutant gelsolin. However, the in vivo platelets clearence assay in 
transplanted mice did not support this hypothesis. Life span of platelets 
overexpressing human cytoplasmic wild type GSN or mutant GSN was not increased 
compared to normal platelets.   
 
On the other hand, gelsolin can play a role in actin polymerization during platelets 
shedding promoting proplatelet branching. Even though, the role of actomyosin in 
platelets biogenesis is not completely understood, actin polymerization is required for 
proplatelets branching and thus may be important for the regulation of platelets 
production 10. It has been shown that megakaryocytes treated with one of the actin 
toxins cytochalasin and latrunculin can extend long proplatelets, but fail to branch 13. 
In addition, Zunino et al showed the involvement of scinderin, a Ca2+-dependent 
filamentus actin severing protein similar to gelsolin, in megakaryocytes apoptosis and 
platelets fragmentation. Scinderin was found to be expressed in human BM cells 
together with the megakaryocytes-specific markers, but absent from 
megakaryoblastic leukemia cells and megakaryocytic cell lines (Meg-01, HEL, K562 
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and HL-60) incapable of producing platelets in culture. Expression of scinderin in the 
Meg-01 cell line decreased cell proliferation and induced cell polyploidization, 
differentiation and apoptosis inducing the release of platelet-like particles 72.  
According to these observations, mutant gelsolin could increase platelets production 
by playing a role in the actin dynamics. In support of this model, the in vitro platelets 
biogenesis assay showed that DAMI cells expressing the mutant GSN release higher 
amounts of platelets-like particles in the culture supernatant compared to DAMI cells 
not transfected and DAMI cells expressing wild type GSN. The role of the mutant 
gelsolin and the actin polymerization is still not completely understood. However, the 
generation of transgenic mice expressing the mutant gelsolin supported a role of this 
alteration also in vivo. Mice expressing the mutant GSN developed a mild phenotype 
showing an increase in platelet counts without any alteration in other cell lineages.  
 
In the affected family members HT shows an early onset in life with only a mild 
thrombocytosis. Therefore, the moderate phenotype observed in the transgenic mice 
fits into this clinical picture. One factor that can influence the severity of the 
phenotype could be the genetic background of the mice. This is a possibility that is 
worth to investigate since it has been reported that the genetic landscape plays a role 
in the development of myeloproliferative disorders in humans. As a matter of fact, on 
the background of a JAK2 or MPL mutation and/or of any other pre-existing or 
additional molecular abnormality, individual-related characteristics contribute to the 
phenotypic pleiotropy of the MPDs. This was supported also by results in animal 
models. Depending on the genetic background of mice transplanted with JAK2V617F 
transfected cells, the characteristics of their myeloproliferative disease were 
somewhat different. In addition to polycythemia, the JAK2V617F allele induced 
marked leukocytosis and marrow reticulin fibrosis in Balb/c mice, while leukocytosis 
was minimal and fibrosis was limited to the spleen in case of C56Bl/6 strain 73. It has 
been proved that the genetic background can cause considerable variation in the 
phenotype of genetically engineered mice, possibly due to the presence of multiple 
functional interactions of different alleles at modifier loci 74. Indeed, the phenotype of 
GSN−/− mice can vary significantly depending on the genetic background. To 
investigate the critical function of gelsolin in a vertebrate organism in the presence of 
numerous other protein that also regulate actin assembly, transgenic gelsolin null 
mice (GSN−/−) were generated in the C57BL/6 outbred genetic background and found 
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to have normal development and longevity. However lack of GSN caused 
physiological dysfunction during hemostasis and activation of platelets, inflammation 
response and leukocytes mobility. Interestingly, knockout mice displayed decrease of 
platelet size and impaired function of platelets leading to prolonged bleeding time 75. 
A recent finding showed that transferring the null gelsolin allele into the Balb/c inbred 
genetic background resulted in almost complete loss of embryos, with very few 
GSN−/− mice escaping embryonic lethality. The lack of gelsolin in BALB/c mice 
resulted in a defective erythroid maturation, with persistence of circulating nucleated 
cells in embryonic life and in impaired red blood cell production under stress 
condition in adult mice. In these mice, the gelsolin deficiency alters the actin 
polymerization/depolymerization equilibrium in the erythrocyte causing impaired 
terminal maturation. These data provide a new link between gelsolin and the 
hematological system and suggest a non-redundant role of the protein in terminal 
erythroid differentiation 76. Since the influence of the genetic background could play a 
major role on the phenotype, it could be possible that backcrossing G5 transgenic 
mice with BALB/c mice would lead to an exasperation of the phenotype in these 
mice.  
Furthermore, the presence of two endogenous copies of wild type gelsolin in the 
mice could compete with the human mutant gene and thus repress the phenotype. 
Therefore, it would be interesting to cross G5 mice with GSN−/− mice in order to 
reproduce the genetic condition present in patients with the heterozygous mutation.  
 
Another possibility to take into consideration is that the mechanisms regulating 
platelet production may not be the same between mice and humans. In 2010, Bender 
et al proved that ADF/n-cofillin-dependent actin turnover determines platelets 
formation and sizing in mice. Their results showed that platelet counts in mice lacking 
both ADF and n-cofillin in megakaryocytes were dramatically reduced indicating that 
in vivo actin turnover is a critical step in the terminal phase of platelets formation. 
They conclude that no other actin severing/depolymerizing protein in platelets such 
as gelsolin or adseverin can functionally compensate for the role of ADF/n-cofillin in 
platelets morphogenesis 77. In humans, evidence supports an important role of 
gelsolin and related proteins in the regulation of platelet formation 72. Therefore it 
could be possible that in mice ADF/cofillin family proteins are the major key-player in 
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platelets formation, whereas in humans this process is mainly regulated by gelsolin 
family proteins. 
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5. CONCLUSION 
 
 
 
 
My studies demonstrate that genetic linkage analysis combined with the use of 
targeted next generation sequencing is a powerful tool to detect the chromosomal 
location of disease genes involved in the pathogenesis of hereditary 
thrombocythemia. The discovery of a new mutation G254C in gelsolin gene was 
possible because of solid results of these genetic analyses and facilitated also by the 
large size of the family. In my work, I characterized this alteration involved in the 
pathogenesis of HT. In order to investigate the functional relevance of the mutation, 
in vitro and in vivo studies have been performed. The platelets biogenesis assay in 
vitro showed that DAMI cells overexpressing the mutant GSN release higher 
amounts of platelets-like particles in the supernatant compared to DAMI cells 
overexpressing wild type GSN. To further characterize the role of the mutation in 
vivo, BAC-transgenic mice expressing the human GSN G254C were generated.  
Transgenic mice developed a mild phenotype showing a tendency to elevated 
platelet counts without alterations in any other blood parameters.  Taken together, 
these results provide new evidence that GSN can play a role in platelets biogenesis 
and that the mutation GSN G254C might be the genetic alteration responsible of HT 
in the pedigree studied.  
Even though GSN is the most prominent candidate gene found and is now shown to 
confer the mild phenotype observed in HT, there could be additional alterations not 
detected in the studies. There is a strong likelihood that the co-segregating region 
found on chromosome 9 is correct, but the genetic analysis of this region might be 
incomplete. There could be, in fact, mutations or deletion/insertion that might have 
been missed with the NGS approach. In addition, my studies did not cover the 
regulatory regions of different genes and the possibility that micro RNA could be 
present in the region and dysregulated.  Therefore, the analysis of the co-segregating 
region found could be extended.  For this purpose, the platelets transcriptome could 
be analyzed by NGS obtaining information not only about the sequence itself, but 
also about the gene expression profile. The RNA sequencing can identify and 
quantify both rare and common transcripts and it is possible to characterize all 
Conclusion 
 53 
transcriptional activity, coding and non-coding 78. With this approach it would be 
possible to detect alterations that have been missed with the DNA next generation 
sequencing and to check the gene expression profile in platelets.  
Further investigations are needed to better characterize the G5 transgenic mice and 
obtain better insights about the pathological mechanism of mutant GSN. It would be 
interesting to investigate the number of MKs in the bone marrow of the G5 mice, the 
ploidy status of the marrow MKs and the number of MK precursors in order to gain 
new inputs of how gelsolin can contribute to the development of thrombocytosis. In 
addition, it would be interesting to investigate if the treatment of the transgenic mice 
with the TPO would affect MK expansion and platelet levels to the same extent as it 
does in wild type mice.  
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6. MATERIAL and METHODS 
 
 
 
 
Patients and clinical feature 
This hereditary thrombocytosis family was reported for the first time in 1986 63. Up to 
now, thrombocythemia has been documented in 16 family members in five 
successive generations. The diagnostic criteria of the World Health Organization 
(WHO) were followed for all patients. The study was approved by the local ethics 
committees and all samples were obtained after subjects provided written informed 
consent. 12 affected and 11 unaffected family members were enrolled in the study. 
 
13 families affected by hereditary thrombocytosis with no mutation detected as 
disease-causing gene and 240 sporadic MPD patients were included for further 
genetic analysis. 443 normal controls were used as reference.  
 
Separation of blood cells and extraction of DNA and RNA 
Blood cells were separated by standard protocols using Histopaque (Sigma, St. 
Louis, MO, USA) gradient centrifugation. Granulocytes and peripheral blood 
mononuclear cells were collected. Platelets were collected using Sepharose 
(Amersham Pharmacia Biotech AB, Uppsala, Sweden) gel filtration method 79. DNA 
was extracted using the QIAamp DNA Mini Kit (QUIAGEN AG, Hombrechtikon CH). 
RNA was isolated using the TRIfast reagent (peqLab Biotechnology GmbH, 
Erlangen, Germany). 
 
Microsatellite analysis 
DNA was amplified by PCR using dye-labeled primers for microsatellite markers. The 
conditions were 94°C for 15 s, 55°C for 15 s, 72°C for 30 s for 10 cycles, 89°C for 15 
s, 55°C for 15 s and 72°C for 30 s for 20 cycles. The PCR products were analyzed 
using the ABI 3100 genetic analyzer and the Genemapper software package version 
3.5 (Applied Biosystems, Foster City, CA, USA). Linkage analysis was carried out 
with FASTLINK software package version 4.1p assuming equal allele frequencies for 
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the marker alleles and an autosomal dominant inheritance model with 100% 
penetrance. 
 
SNP CHIP Array 
The Affymetrix GeneChip Human Mapping 50K Xba 240 was used to genotype 
single nucleotide polymorphisms (SNPs) in genomic DNA according to the Affymetrix 
GeneChip Mapping Assay Manual (Affymetrix Inc., Santa Clara, CA, USA). The SNP 
calls were generated by GeneChip DNA Analysis Software. dCHIP version 2005 was 
used to perform parametric linkage analysis 80 . An autosomal dominant inheritance 
model with a 100% penetrance was used.  
 
Next Generation Sequencing 
The enrichment of DNA of the region of interest was performed with two different 
platforms: Nimblegen enrichment and Agilent enrichment. Briefly, genomic DNA was 
fragmented using Covaris instrument (Covaris, Woburn MA  USA). Fragments were 
blunt-end repaired and modified with dA-overhang in order to ligate them with paired-
end adapters. The DNA prepped was subsequently hybridized to a specific 
biotinylated RNA library to enrich it for the region of interest on cromosome 9. The 
sequencing step was performed with Illumina and Roche454 Technology according 
to the manufacturer’s protocol. The data were analyzed using CLC DNA Workbench 
4 (CLC bio, Aarhus Denmark). 
 
Genomic DNA sequencing 
Candidate genes were sequenced from PCR fragments amplified from genomic 
DNA. PCR conditions were 95ºC for 2 m, 94ºC for 30 s, 60ºC for 30 s and 72ºC for 
45 s for 35 cycles. Sequencing was performed on Applied Biosystems 3700 DNA 
sequencer (Applied Biosystems, Foster City, CA, USA) according to the 
manufacturer’s protocols.  
 
cDNA synthesis, and Quantitative RT-PCR 
Total RNA (2 µg) was reverse transcribed to generate cDNA using High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). 
Quantitative PCR was performed with the Power SYBR green master mix on a 7500 
Fast machine (Applied Biosystems, Foster City, CA). The differences of threshold 
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cycles (ΔCT) were derived by subtracting the CT value for the internal reference, 
ribosomal protein L19 (RPL19), from the CT values of the marker gene gelsolin 
(GSN). Relative expression level for each reaction was calculated as 2-CT. The 
primers were designed across exon-intron junctions 81. Sequences of the primers are 
listed in Table 1. 
 
Human GSN_F GGTTCCAACAGCAATCGGTA 
Human GSN_R GTTTGCCTGCTTGCCTTTC 
Human RPL19_F GATGCCGGAAAAACACCTTG 
Human RPL19_F TGGCTGTACCCTTCCGCTT 
Tab 1: Primers for gelsolin expression analysis in plateles cDNA from normal controls and ET 
patients 
 
 
DNA construct 
Human gelsolin cDNA clone in pOTB7 vector was purchased from RZPD (Germany). 
The full length secreted and cytoplasmic gelsolin cDNA wild type and mutant 
(G254C) were cloned into retroviral vector pMSCVpuro and MSCV2.2iresGFP 
encoding green fluorescent protein (kindly provided by Dr. J. Cools, Flanders 
Interuniversity Institute for Biotechnology, Leuven, Belgium).  
 
Stable transfected cell line 
Cell lines (293T and DAMI) were transfected with vectors containing cytoplasmic wild 
type and mutant GSN cDNA using Turbofect following the manufacturer’s protocol 
(Fermentas Life Science, St. Leon-Rot  Germany). After transfection, cells were 
grown in puromycine selection media. Clones were analysed for gelsolin expression 
by Western Blot (WB). 
  
Protein extraction and Western blot 
Whole cell lysates were extracted in RIPA buffer (25mM Tris-HCl, pH 7.6, 150 mM 
NaCl, 1% NP40, 0.1% sodium deoxycholate, 0.1% SDS). Preparation of cytoplasmic 
and nuclear cell extracts was obtained with the use of two different solutions: hypo-
osmotic buffer (20mM Hepes pH 7.9, 10mM KCl, 0,1mM NaVO4, 1mM EDTA, 1mM 
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EGTA, 0.2% NP40, 10% glycerol) to isolate cytoplasmic proteins and hyper-osmotic 
buffer (420mM NaCl, 20mM Hepes pH 7.9, 10mM KCl, 0,1mM NaVO4, 1mM EDTA, 
1mM EGTA, 20% glycerol) to isolate the nuclear extracts.  
Indicated amount of protein were separated by 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose 
membrane. The following antibodies were used as primary antibodies: goat 
polyclonal anti-human gelsolin antibody (clone C20, Santa Cruz Biotechnology, CA, 
USA), mouse monoclonal anti-actin antibody (Clone AC-15, Sigma-Aldrich, Buchs 
CH). IRDye fluorescent secondary antibodies were used and membranes were 
scanned with the Odyssey infrared imaging system (LI-COR Bioscience, Nebraska 
USA). 
 
In-vitro Caspase3 cleavage assay 
Protein lysates were obtained from GSN wild type and mutant stable transfected 
293T cell lines by a step of sonication in Caspase3 reaction buffer (50mM Hepes, pH 
7.2, 50 mM NaCl, 0.1% Chaps, 10 mM EDTA, 5% glycerol and 10 mM DTT). A 
reaction containing 50 g of proteins and 2 units of active recombinant human 
Caspase-3 (BioVision, Milpitas, CA USA) was incubated at 37°C. At 0, 5min, 15min, 
30min, 1hour 10 g of proteins have been removed, cooked at 95°C 5 min and 
analyzed by SDS-PAGE.  
 
Platelets biogenesis in DAMI cells 
DAMI cells were cultured in IMDM supplemented with 10% Horse Serum (Gibco) and 
penicillin-streptomycin (100units/ml and 100g/ml, respectively, Gibco) at 37°C in a 
humidified atmosphere with 5% CO2. DAMI cells differentiation trough 
megakaryocytic lineage was induced with 1 M PMA and 10 ng/ml TPO during 7 
days and cultured for another 3 days without stimulation to evaluate the 
characteristics of the particles produced 67. Platelets-like particles were quantified in 
the supernatant by flow cytometry. Particles were identified by their positivity to CD41 
and CD61 and by their size and granulation. Counts were obtained during 30sec in a 
continuous flow (60l/min) (FACSCalibur, BD Bioscience). 
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Retroviral transduction and bone marrow transplantation 
GFP retroviral vectors containing human cytoplasmic GSN cDNA or human 
cytoplasmic GSN G254C cDNA were used for bone marrow transplantation as 
previously described 73. Briefly, the viral titer was estimated by transducing BaF3 
cells with MSCV_GFP retroviral supernatant plus polybrene (10g/ml) and analyzed 
for the percentage of green fluorescent positive cells by FACS two days after 
transduction. C57BL/6 donor mice (Charles River, Germany) were treated with 5-
fluorouracil (150 mg/kg) 5 days prior to harvest.  Bone marrow cells from donor mice 
were harvested by crashing femurs and tibias and cultured 1 day in transplant media 
(RPMI 10%FCS, 6ng/ml IL3, 10ng/ml IL6 and 10ng/ml stem cell factor). Cells were 
treated with spin infection with 1ml retroviral supernatant and centrifuge 1800 g 90 
minutes at 30°C, 24 hours before and on day of transplantation. Recipient mice were 
lethally irradiated (2x6Gy) and transplanted with 1 x 106 whole BM cells. Mice were 
maintained on water plus addition of Nopil (Mepha, Aesch BL, CH). 
 
Platelets Clearence  
Mice were injected intravenously with 600 g N-hydroxysuccinimido-biotin (NHS-
biotin) (Sigma). At different time point 10l of whole blood were collected and mixed 
in BSGC buffer (116 mM NaCl, 13.6 mM tri-sodium citrate, 8.6 mM Na2HPO4, 1.6 
mM KH2PO4, 0.9 mM EDTA, 11.1 mM glucose). 2μl of blood were washed in 
balanced salt solution (BSS: 149 mM NaCl, 3.7 mM KCl, 2.5 mM CaCl2, 1.2 mM 
MgSO4, 7.4 mM HEPES, 1.2 mM KH2PO4, 0.8 mM K2HPO4, 3% bovine calf serum), 
pelleted at 1210 g for 10 min, and stained with PE-coniugated anti-CD61 (BD) and 
APC-conjugated streptavidin (BD) for 1 hr on ice. Samples were washed again in 
BSS and flow cytometry was performed on FACSCalibur (BD Bioscience) 15. 
 
Transgenic mice 
The human GSN-G254C transgene was constructed using the BAC CTD2218E19 
(Invitrogen human BAC clones, Grand Island, NY  USA), which is approximately 
130-kb long and contains part of the GSN gene reaching from 70 kb upstream of 
exon 1 to 700 bp of the last intron. The construct was repaired with a fragment 
containing the last exon 18 derived from the BAC RP11269G20 and an ampicillin 
resistance cassette flanked by Frt sites (from the plasmid 
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phCre.myc.nuc.FRT.AMP.FRT, kindly provided by Dr Günther Schütz, DKFZ, 
Heidelberg, Germany), and 100 bp of sequence homologous to the BAC vector 
pBeloBAC11. This construct was inserted into the BAC by homologous 
recombination in the bacterial strain SW105 (kindly provided by National cancer 
Institute NCI Frederick, Maryland USA), and the ampicillin cassette was 
subsequently removed by induction of Flpe recombinase 82. The insertion of the 
desired mutation was obtained by a new recombineering-based E.coli BAC 
modification system using galK selection 83. For oocyte injection, BAC DNA was 
linearized with PmeI (NEB, Ipswich MA) and purified over a Sepharose CL4b column 
(GE Healthcare, Little Chalfont, United Kingdom). Genotyping of transgenic mice was 
performed using three sets of primers pair covering all the transgene. A set of 
primers pair for -globin was used to check the DNA quality and exclude false 
negative results (Tab 2).  
 
5’UTR_F TAGCGTGCCATGTTTCTCTG 
5’UTR_R ACAGCAAATTGGGGTCACTC 
Exon6_F GGCGGGGCTTATAGGAAG 
Exon6_R CAAATTCACCTCAAATTGCC 
Exon18_F TGGGCAGTAGGGACAGTAGG 
Exon18_R AGGGACACAGGCAGAGAAGA 
-globin_F GCTTTCCAGCAGGCACTAAC 
-globin_R AGAATAGCCAGGGGAAGGAA 
Tab 2: primers used for genotyping 
 
Transgene copy number analysis was performed with a quantitative PCR using the 
following primers: TAGCGTGCCATGTTTCTCTG, ACAGCAAATTGGGGTCACTC. 
The number of transgene copy per genome was assessed in the “Absolute 
Quantification” setup with standard curves made from human genomic DNA isolated 
from a normal control. 
Expression level of the human gelsolin gene in mice was performed with Real Time 
PCR using GSN primers specific for human sequence in order to distinguish the 
expression of human gelsolin in transgenic mouse samples. Murine GSN expression 
was detected with primers selective for the mouse transcript. Each GSN primers pair 
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was tested to have the same efficiency. Therefore, ratios of human and mouse GSN 
were assessed in the “Relative quantification” setup using the 2-CT method. Primers 
pair are summarizes in Table 3. 
All mice used in this study were kept under specific pathogen-free conditions and in 
accordance to Swiss federal regulations. 
 
HumanGSN_F GGTTCCAACAGCAATCGGTA 
HumanGSN_R GTTTGCCTGCTTGCCTTTC 
MouseGSN_F GTACCTTTCGATGCTGCTACG 
MouseGSN_R AGGTGCCACCCTTGTAGATG 
MouseRPL19_F ATCCGCAAGCCTGTGACTGT 
MouseRPL19_R TCGGGCCAGGGTGTTTTT 
Tab 3: primers used for hGSN expression in transgenic mice 
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